Regulatory

May 21, 2026

Positive 52-week Phase 2b/3 Data of Izokibep in Psoriatic Arthritis to be Presented at EULAR 2026

Stockholm, Sweden, May 21, 2026. Affibody AB (“Affibody”) today announced that positive 52-week data from a global Phase 2b/3 study of izokibep in psoriatic arthritis (PsA) will be presented...

Read more

Regulatory

April 21, 2026

NOTICE OF ANNUAL GENERAL MEETING IN AFFIBODY MEDICAL AB (PUBL)

The shareholders of Affibody Medical AB (publ), corporate identity number 556714-5601 (the “Company” or “Affibody”) are hereby invited to attend the annual general meeting of the shareholders on Monday...

Read more

Regulatory

March 27, 2026

Izokibep Demonstrates Durable Efficacy in Phase 3 Study in Hidradenitis Suppurativa as Presented at AAD 2026

Stockholm, Sweden, March 27, 2026. Affibody AB (“Affibody”) today announced positive 32-week data from a global Phase 3 study of the next generation IL-17A inhibitor izokibep in hidradenitis suppurativa...

Read more

Regulatory

February 19, 2026

Affibody Signs Letter of Intent with SHINE Technologies for Supply of Lutetium-177

Stockholm, Sweden, February 19, 2026. Affibody AB (“Affibody”) today announced that a Letter of Intent (LOI) has been signed with SHINE Technologies, LCC (“SHINE”) as an additional supplier of...

Read more

Regulatory

February 17, 2026

Affibody’s licensee Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

Stockholm, Sweden, February 17, 2026. Affibody’s licensee Rallybio Corporation (Rallybio) has today announced positive results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) clinical study evaluating RLYB116, an innovative, once-weekly,...

Read more

News

February 12, 2026

Affibody Medical announces outcome of rights issue

Stockholm, Sweden, February 12, 2026. Affibody Medical AB (publ) (”Affibody” or the “Company”) today announced the outcome of the Company’s rights issue of approximately SEK 307 million (the “Rights...

Read more

News

February 5, 2026

Report from Extraordinary General Meeting in Affibody Medical AB (publ)

Stockholm, Sweden, February 5, 2026. Affibody Medical AB (publ) today held an Extraordinary General Meeting. The following resolutions were adopted. The General Meeting resolved on the introduction of an...

Read more

Regulatory

January 20, 2026

Affibody Carries Out Fully Guaranteed Rights Issue of SEK 307 Million

Stockholm, Sweden, January 20, 2026. Affibody Medical AB (publ) (“Affibody”) today announced that the Board of Directors, with authorization from the annual general meeting on May 27, 2025, has...

Read more

News

January 19, 2026

NOTICE OF EXTRAORDINARY GENERAL MEETING IN AFFIBODY MEDICAL AB (PUBL)

The shareholders of Affibody Medical AB (publ), corporate identity number 556714-5601 (the “Company” or “Affibody”) are hereby invited to attend an extraordinary general meeting of the shareholders on Thursday...

Read more